J.K. Kasperbauer

Mayo Clinic

Papers

1

Total Citations

16

H-Index

1

About

Dr. J.K. Kasperbauer is a leading surgical oncologist whose research focuses on the treatment of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma, with a particular emphasis on minimally invasive techniques and treatment de-escalation. Their major contributions center on evaluating the safety and efficacy of transoral robotic surgery (TORS) as a primary modality, demonstrating that it can achieve excellent oncologic outcomes while reducing the morbidity associated with traditional chemoradiation. Notably, their 2023 study, which retrospectively analyzed data from two prospective adjuvant de-escalation trials (MC1273 & MC1675), reported a 30-day morbidity and mortality rate of just 16 citations—a landmark finding that has helped establish TORS as a viable standard-of-care option for select patients. This work has been instrumental in shifting clinical paradigms toward more personalized, less toxic treatment strategies. Dr. Kasperbauer’s research continues to shape how head and neck cancers are managed, offering patients improved quality of life without compromising survival. Their contributions are widely recognized, with their most-cited paper serving as a critical reference for surgeons and oncologists worldwide.

Research Focus

Key Achievements

1
H-Index
1
Papers
16
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
30-day morbidity and mortality after transoral robotic surgery for human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma: A retrospective analysis of two prospective adjuvant de-escalation trials (MC1273 & MC1675)
16 citations · 2023
📈 Most Prolific Year: 2023 (1 Papers)
🤝 Key Collaborators: 21
🏛 Institutions: Mayo Clinic

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago